| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Models, Statistical | 66 | 2022 | 5102 | 4.240 |
Why?
|
| Causality | 29 | 2024 | 1275 | 3.170 |
Why?
|
| Data Interpretation, Statistical | 33 | 2022 | 2716 | 2.760 |
Why?
|
| Epidemiologic Methods | 27 | 2013 | 1364 | 1.990 |
Why?
|
| Probability | 21 | 2012 | 2505 | 1.120 |
Why?
|
| Biometry | 13 | 2010 | 558 | 1.060 |
Why?
|
| Epidemiologic Research Design | 5 | 2017 | 367 | 1.040 |
Why?
|
| Randomized Controlled Trials as Topic | 23 | 2021 | 9959 | 1.040 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2016 | 1203 | 0.950 |
Why?
|
| Research Design | 17 | 2023 | 5987 | 0.920 |
Why?
|
| Antiretroviral Therapy, Highly Active | 10 | 2015 | 1873 | 0.880 |
Why?
|
| Nose Neoplasms | 2 | 2023 | 246 | 0.870 |
Why?
|
| Cavernous Sinus | 1 | 2023 | 125 | 0.840 |
Why?
|
| Zidovudine | 7 | 2004 | 620 | 0.820 |
Why?
|
| Acquired Immunodeficiency Syndrome | 11 | 2011 | 2232 | 0.820 |
Why?
|
| Decompressive Craniectomy | 1 | 2020 | 72 | 0.710 |
Why?
|
| Braces | 1 | 2020 | 135 | 0.700 |
Why?
|
| Epidemiologic Studies | 4 | 2010 | 676 | 0.700 |
Why?
|
| Patient Dropouts | 3 | 2012 | 421 | 0.690 |
Why?
|
| CD4 Lymphocyte Count | 19 | 2019 | 2559 | 0.670 |
Why?
|
| Intention to Treat Analysis | 2 | 2017 | 426 | 0.660 |
Why?
|
| Selection Bias | 7 | 2015 | 371 | 0.640 |
Why?
|
| Anti-HIV Agents | 15 | 2019 | 4256 | 0.630 |
Why?
|
| Likelihood Functions | 5 | 2018 | 1005 | 0.610 |
Why?
|
| Regression Analysis | 11 | 2018 | 6459 | 0.600 |
Why?
|
| Sphenoid Sinus | 1 | 2017 | 99 | 0.590 |
Why?
|
| Progestins | 2 | 2016 | 306 | 0.540 |
Why?
|
| Clinical Trials as Topic | 7 | 2012 | 7913 | 0.540 |
Why?
|
| Craniosynostoses | 1 | 2020 | 401 | 0.530 |
Why?
|
| Survival Analysis | 15 | 2020 | 10252 | 0.520 |
Why?
|
| Computer Graphics | 2 | 2007 | 361 | 0.520 |
Why?
|
| Cerebral Palsy | 1 | 2020 | 459 | 0.520 |
Why?
|
| Air Pollution | 2 | 2022 | 2286 | 0.510 |
Why?
|
| HIV Infections | 22 | 2019 | 16718 | 0.510 |
Why?
|
| Bayes Theorem | 8 | 2017 | 2309 | 0.500 |
Why?
|
| Mortality | 4 | 2017 | 2864 | 0.500 |
Why?
|
| Comparative Effectiveness Research | 3 | 2016 | 681 | 0.490 |
Why?
|
| Endoscopy | 4 | 2022 | 1785 | 0.480 |
Why?
|
| Observation | 4 | 2017 | 312 | 0.460 |
Why?
|
| Personnel, Hospital | 1 | 2015 | 283 | 0.450 |
Why?
|
| Pituitary Neoplasms | 2 | 2021 | 1345 | 0.440 |
Why?
|
| Viral Load | 10 | 2019 | 3299 | 0.420 |
Why?
|
| Disease Outbreaks | 5 | 2008 | 1772 | 0.420 |
Why?
|
| Clinical Protocols | 1 | 2017 | 1462 | 0.400 |
Why?
|
| Statistics as Topic | 12 | 2016 | 2373 | 0.380 |
Why?
|
| Cross-Over Studies | 3 | 2022 | 2029 | 0.380 |
Why?
|
| Adenoma | 2 | 2021 | 2174 | 0.380 |
Why?
|
| Vaccines | 3 | 2023 | 822 | 0.360 |
Why?
|
| Vietnam Conflict | 1 | 2010 | 99 | 0.360 |
Why?
|
| Humans | 150 | 2024 | 744343 | 0.350 |
Why?
|
| Longitudinal Studies | 17 | 2022 | 13989 | 0.350 |
Why?
|
| Computer Simulation | 13 | 2021 | 6196 | 0.340 |
Why?
|
| Heroin Dependence | 1 | 2010 | 175 | 0.340 |
Why?
|
| Treatment Refusal | 4 | 2006 | 421 | 0.340 |
Why?
|
| Communicable Diseases | 2 | 2008 | 880 | 0.340 |
Why?
|
| Weight Gain | 3 | 2020 | 2292 | 0.310 |
Why?
|
| HIV-1 | 9 | 2017 | 6939 | 0.300 |
Why?
|
| Anti-Retroviral Agents | 3 | 2015 | 1715 | 0.290 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 2356 | 0.280 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2012 | 967 | 0.280 |
Why?
|
| RNA, Viral | 3 | 2019 | 2902 | 0.260 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 2000 | 249 | 0.260 |
Why?
|
| Case-Control Studies | 12 | 2024 | 21746 | 0.260 |
Why?
|
| Cranial Fossa, Middle | 1 | 2023 | 28 | 0.230 |
Why?
|
| Linear Models | 3 | 2007 | 5952 | 0.230 |
Why?
|
| Benzoxazines | 2 | 2016 | 301 | 0.220 |
Why?
|
| Proportional Hazards Models | 12 | 2011 | 12354 | 0.220 |
Why?
|
| Pharmacoepidemiology | 1 | 2006 | 323 | 0.220 |
Why?
|
| Biostatistics | 1 | 2024 | 162 | 0.210 |
Why?
|
| Epidemiology | 4 | 1989 | 287 | 0.210 |
Why?
|
| Mathematics | 8 | 2009 | 728 | 0.210 |
Why?
|
| Stroke | 3 | 2020 | 9981 | 0.210 |
Why?
|
| Particulate Matter | 1 | 2013 | 2530 | 0.210 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2016 | 3255 | 0.200 |
Why?
|
| Drug Monitoring | 2 | 2019 | 956 | 0.200 |
Why?
|
| Decision Making | 4 | 2019 | 3887 | 0.200 |
Why?
|
| Dementia | 1 | 2015 | 2518 | 0.200 |
Why?
|
| Risk | 12 | 1999 | 9687 | 0.200 |
Why?
|
| Stochastic Processes | 5 | 2008 | 344 | 0.190 |
Why?
|
| Citrus sinensis | 1 | 2020 | 16 | 0.190 |
Why?
|
| Environmental Exposure | 6 | 2004 | 4234 | 0.190 |
Why?
|
| Smoking Cessation | 3 | 2020 | 2071 | 0.190 |
Why?
|
| Comorbidity | 5 | 2013 | 10388 | 0.180 |
Why?
|
| Rhizotomy | 1 | 2020 | 30 | 0.180 |
Why?
|
| Pituitary Hormones | 1 | 2021 | 183 | 0.180 |
Why?
|
| Malus | 1 | 2020 | 48 | 0.180 |
Why?
|
| Air Pollutants | 2 | 2013 | 2817 | 0.180 |
Why?
|
| Visual Field Tests | 1 | 2022 | 383 | 0.180 |
Why?
|
| Frontal Bone | 1 | 2020 | 105 | 0.180 |
Why?
|
| Multicenter Studies as Topic | 4 | 2007 | 1677 | 0.180 |
Why?
|
| Statistics, Nonparametric | 5 | 2006 | 2886 | 0.170 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 401 | 0.170 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 1261 | 0.170 |
Why?
|
| Quality of Life | 2 | 2020 | 12804 | 0.170 |
Why?
|
| Craniotomy | 1 | 2023 | 729 | 0.170 |
Why?
|
| HIV Seropositivity | 2 | 2016 | 971 | 0.170 |
Why?
|
| Models, Theoretical | 5 | 2017 | 3589 | 0.160 |
Why?
|
| Female | 47 | 2021 | 380194 | 0.160 |
Why?
|
| Logistic Models | 6 | 2013 | 13408 | 0.160 |
Why?
|
| Models, Genetic | 3 | 2007 | 3494 | 0.160 |
Why?
|
| Coronary Disease | 4 | 2016 | 6077 | 0.160 |
Why?
|
| Therapeutic Equivalency | 1 | 1998 | 141 | 0.150 |
Why?
|
| Genetics | 1 | 1998 | 112 | 0.150 |
Why?
|
| Patient Simulation | 1 | 2020 | 309 | 0.150 |
Why?
|
| Educational Status | 1 | 2005 | 2540 | 0.150 |
Why?
|
| Treatment Outcome | 18 | 2020 | 63114 | 0.150 |
Why?
|
| Time Factors | 18 | 2018 | 40075 | 0.150 |
Why?
|
| Occupational Diseases | 7 | 1989 | 1471 | 0.150 |
Why?
|
| Breast Neoplasms | 7 | 2016 | 20822 | 0.150 |
Why?
|
| Orbit | 1 | 2020 | 426 | 0.140 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2000 | 657 | 0.140 |
Why?
|
| Linkage Disequilibrium | 1 | 2001 | 1997 | 0.140 |
Why?
|
| Models, Biological | 4 | 2007 | 9583 | 0.140 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2018 | 194 | 0.140 |
Why?
|
| Medroxyprogesterone | 1 | 2016 | 37 | 0.140 |
Why?
|
| AIDS-Related Complex | 1 | 2016 | 110 | 0.140 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 973 | 0.140 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 6487 | 0.140 |
Why?
|
| Evaluation Studies as Topic | 2 | 2012 | 1681 | 0.140 |
Why?
|
| Learning Curve | 1 | 2017 | 208 | 0.140 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 2158 | 0.130 |
Why?
|
| Influenza, Human | 4 | 2010 | 1479 | 0.130 |
Why?
|
| Male | 45 | 2024 | 350118 | 0.130 |
Why?
|
| Visual Fields | 1 | 2022 | 1047 | 0.130 |
Why?
|
| Drug Administration Schedule | 5 | 2012 | 4933 | 0.130 |
Why?
|
| Education, Nursing | 1 | 2015 | 82 | 0.130 |
Why?
|
| Drug Therapy, Combination | 5 | 2016 | 6489 | 0.130 |
Why?
|
| Sarcoma, Kaposi | 1 | 1998 | 370 | 0.130 |
Why?
|
| Forced Expiratory Volume | 3 | 1992 | 1743 | 0.130 |
Why?
|
| Bone Transplantation | 1 | 2020 | 907 | 0.130 |
Why?
|
| Critical Illness | 1 | 2007 | 2670 | 0.120 |
Why?
|
| Algorithms | 9 | 2010 | 13881 | 0.120 |
Why?
|
| Nonlinear Dynamics | 1 | 1997 | 502 | 0.120 |
Why?
|
| Ecology | 1 | 1994 | 106 | 0.120 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2016 | 615 | 0.110 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 4740 | 0.110 |
Why?
|
| Thrombophlebitis | 1 | 1993 | 309 | 0.110 |
Why?
|
| Risk Factors | 20 | 2020 | 72290 | 0.110 |
Why?
|
| United States | 16 | 2023 | 69872 | 0.110 |
Why?
|
| Middle Aged | 32 | 2021 | 213383 | 0.100 |
Why?
|
| Dermoid Cyst | 1 | 2013 | 93 | 0.100 |
Why?
|
| Neurosurgical Procedures | 1 | 2023 | 2002 | 0.100 |
Why?
|
| Developed Countries | 4 | 2017 | 437 | 0.100 |
Why?
|
| Cohort Studies | 13 | 2016 | 40561 | 0.100 |
Why?
|
| Health Status | 1 | 2005 | 4034 | 0.100 |
Why?
|
| Hospital Mortality | 1 | 2005 | 5317 | 0.100 |
Why?
|
| Life Style | 3 | 2020 | 3835 | 0.100 |
Why?
|
| Job Satisfaction | 1 | 2015 | 535 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2017 | 1915 | 0.100 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2012 | 213 | 0.100 |
Why?
|
| Europe | 5 | 2017 | 3339 | 0.100 |
Why?
|
| Cause of Death | 6 | 2017 | 3584 | 0.100 |
Why?
|
| Brain Ischemia | 1 | 2005 | 3265 | 0.100 |
Why?
|
| Hydrocephalus | 1 | 2018 | 748 | 0.100 |
Why?
|
| Confidence Intervals | 3 | 2010 | 2971 | 0.100 |
Why?
|
| Military Personnel | 1 | 2020 | 1133 | 0.100 |
Why?
|
| Nevirapine | 1 | 2012 | 267 | 0.100 |
Why?
|
| Adult | 37 | 2021 | 214055 | 0.100 |
Why?
|
| Postmenopause | 2 | 2016 | 2461 | 0.100 |
Why?
|
| Sample Size | 2 | 2021 | 845 | 0.100 |
Why?
|
| Cardiovascular Diseases | 4 | 2008 | 15165 | 0.100 |
Why?
|
| Exercise | 5 | 2020 | 5615 | 0.100 |
Why?
|
| Cognition Disorders | 1 | 2005 | 4043 | 0.090 |
Why?
|
| Forecasting | 1 | 2020 | 2951 | 0.090 |
Why?
|
| Fishes | 1 | 2013 | 569 | 0.090 |
Why?
|
| Oseltamivir | 1 | 2010 | 75 | 0.090 |
Why?
|
| Scalp | 1 | 2013 | 380 | 0.090 |
Why?
|
| Family Characteristics | 2 | 2012 | 1000 | 0.090 |
Why?
|
| Mathematical Computing | 2 | 2007 | 147 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2002 | 4386 | 0.090 |
Why?
|
| Patient Compliance | 2 | 2017 | 2684 | 0.090 |
Why?
|
| Smoking | 11 | 2013 | 8987 | 0.080 |
Why?
|
| Nose | 1 | 2013 | 509 | 0.080 |
Why?
|
| Propensity Score | 1 | 2016 | 1781 | 0.080 |
Why?
|
| Adolescent | 7 | 2023 | 85781 | 0.080 |
Why?
|
| Obesity | 3 | 2018 | 12745 | 0.080 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 1917 | 0.080 |
Why?
|
| Epistasis, Genetic | 1 | 2010 | 365 | 0.080 |
Why?
|
| Mass Screening | 1 | 2004 | 5255 | 0.080 |
Why?
|
| Incidence | 5 | 2021 | 20947 | 0.080 |
Why?
|
| Data Collection | 3 | 2001 | 3341 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2021 | 15295 | 0.070 |
Why?
|
| Random Allocation | 6 | 1990 | 2429 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2008 | 275 | 0.070 |
Why?
|
| Sensitivity and Specificity | 5 | 2004 | 14722 | 0.070 |
Why?
|
| Temperature | 1 | 2013 | 2206 | 0.070 |
Why?
|
| Life Expectancy | 2 | 1991 | 1184 | 0.070 |
Why?
|
| Population Density | 1 | 2007 | 196 | 0.070 |
Why?
|
| Chicago | 1 | 2007 | 240 | 0.070 |
Why?
|
| Weight Loss | 2 | 2016 | 2622 | 0.070 |
Why?
|
| Mining | 1 | 1987 | 88 | 0.070 |
Why?
|
| Heparin | 1 | 1993 | 1637 | 0.070 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 459 | 0.070 |
Why?
|
| Disease Transmission, Infectious | 2 | 2010 | 547 | 0.070 |
Why?
|
| Odds Ratio | 5 | 2010 | 9849 | 0.070 |
Why?
|
| Disease | 2 | 2004 | 680 | 0.070 |
Why?
|
| Feeding Behavior | 2 | 2020 | 3188 | 0.070 |
Why?
|
| Urban Population | 1 | 2013 | 2021 | 0.070 |
Why?
|
| Genetic Markers | 1 | 2012 | 2634 | 0.060 |
Why?
|
| Bulimia | 1 | 2007 | 382 | 0.060 |
Why?
|
| Survival Rate | 4 | 2013 | 12788 | 0.060 |
Why?
|
| Diet | 3 | 2018 | 7939 | 0.060 |
Why?
|
| Estrogens | 2 | 2010 | 1566 | 0.060 |
Why?
|
| Analysis of Variance | 4 | 2004 | 6365 | 0.060 |
Why?
|
| Follow-Up Studies | 9 | 2021 | 39050 | 0.060 |
Why?
|
| Body Mass Index | 3 | 2016 | 12720 | 0.060 |
Why?
|
| Double-Blind Method | 4 | 2010 | 12026 | 0.060 |
Why?
|
| Prospective Studies | 11 | 2017 | 53288 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2012 | 19905 | 0.060 |
Why?
|
| Monte Carlo Method | 3 | 2017 | 1254 | 0.060 |
Why?
|
| Environment | 1 | 2010 | 1124 | 0.060 |
Why?
|
| History, 20th Century | 2 | 2010 | 2740 | 0.060 |
Why?
|
| Length of Stay | 1 | 2017 | 6309 | 0.060 |
Why?
|
| Child Development | 2 | 2006 | 2223 | 0.060 |
Why?
|
| Cyanates | 1 | 1983 | 20 | 0.060 |
Why?
|
| Toluene 2,4-Diisocyanate | 1 | 1983 | 10 | 0.060 |
Why?
|
| Alkynes | 2 | 2016 | 306 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2001 | 2618 | 0.060 |
Why?
|
| Markov Chains | 2 | 2017 | 969 | 0.060 |
Why?
|
| Didanosine | 1 | 2003 | 153 | 0.060 |
Why?
|
| Homosexuality, Male | 2 | 2004 | 1240 | 0.060 |
Why?
|
| Germany | 1 | 2005 | 862 | 0.060 |
Why?
|
| Child | 4 | 2020 | 77709 | 0.060 |
Why?
|
| Child, Preschool | 5 | 2020 | 41006 | 0.060 |
Why?
|
| Cyclopropanes | 2 | 2016 | 416 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 9239 | 0.050 |
Why?
|
| Motor Skills | 1 | 2006 | 522 | 0.050 |
Why?
|
| Research Subjects | 1 | 2004 | 239 | 0.050 |
Why?
|
| Nervous System | 1 | 2006 | 554 | 0.050 |
Why?
|
| Infant | 4 | 2020 | 35136 | 0.050 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 137 | 0.050 |
Why?
|
| Hormone Replacement Therapy | 2 | 2013 | 745 | 0.050 |
Why?
|
| Premature Birth | 1 | 2014 | 1721 | 0.050 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 5034 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 3843 | 0.050 |
Why?
|
| Myocardial Infarction | 3 | 2005 | 11727 | 0.050 |
Why?
|
| Air Pollutants, Occupational | 3 | 1989 | 408 | 0.050 |
Why?
|
| Pentamidine | 1 | 2000 | 45 | 0.050 |
Why?
|
| Public Health Practice | 1 | 2003 | 218 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2016 | 7729 | 0.050 |
Why?
|
| Hypertension | 2 | 1998 | 8480 | 0.050 |
Why?
|
| Risk Assessment | 4 | 2017 | 23338 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 1782 | 0.050 |
Why?
|
| Carbon Compounds, Inorganic | 2 | 1989 | 11 | 0.050 |
Why?
|
| Silicon Compounds | 2 | 1989 | 15 | 0.050 |
Why?
|
| Aged | 13 | 2021 | 163280 | 0.040 |
Why?
|
| Heart | 1 | 1993 | 4467 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 2022 | 665 | 0.040 |
Why?
|
| Silicon | 2 | 1989 | 145 | 0.040 |
Why?
|
| Penetrance | 1 | 2000 | 381 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 17446 | 0.040 |
Why?
|
| Risperidone | 1 | 2001 | 383 | 0.040 |
Why?
|
| Graft vs Leukemia Effect | 1 | 1999 | 111 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2010 | 2063 | 0.040 |
Why?
|
| Boston | 2 | 2007 | 9313 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 1998 | 5686 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2006 | 1320 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2006 | 1092 | 0.040 |
Why?
|
| Health Surveys | 1 | 2008 | 4037 | 0.040 |
Why?
|
| Time | 1 | 2020 | 542 | 0.040 |
Why?
|
| Infant, Newborn | 4 | 2014 | 25625 | 0.040 |
Why?
|
| Isoniazid | 1 | 1999 | 274 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2010 | 2987 | 0.040 |
Why?
|
| Aerosols | 1 | 2000 | 625 | 0.040 |
Why?
|
| Eye | 1 | 2022 | 729 | 0.040 |
Why?
|
| Models, Structural | 1 | 1998 | 361 | 0.040 |
Why?
|
| Public Health | 1 | 1991 | 2603 | 0.040 |
Why?
|
| Disease Progression | 4 | 2011 | 13284 | 0.040 |
Why?
|
| Vitamins | 1 | 2006 | 1622 | 0.040 |
Why?
|
| Developmental Disabilities | 1 | 2006 | 1456 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2021 | 77449 | 0.040 |
Why?
|
| Homozygote | 1 | 2001 | 1785 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2004 | 2715 | 0.040 |
Why?
|
| Pregnancy | 4 | 2014 | 29144 | 0.040 |
Why?
|
| Proteins | 1 | 2012 | 6103 | 0.040 |
Why?
|
| Veterans | 1 | 2010 | 2519 | 0.040 |
Why?
|
| Systems Analysis | 1 | 2017 | 172 | 0.030 |
Why?
|
| Family | 1 | 2007 | 3147 | 0.030 |
Why?
|
| Bisexuality | 1 | 1998 | 270 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 1738 | 0.030 |
Why?
|
| Respiration Disorders | 2 | 1989 | 371 | 0.030 |
Why?
|
| Influenza in Birds | 2 | 2006 | 75 | 0.030 |
Why?
|
| Birds | 2 | 2006 | 163 | 0.030 |
Why?
|
| Prognosis | 3 | 2021 | 29063 | 0.030 |
Why?
|
| Research | 1 | 2004 | 1999 | 0.030 |
Why?
|
| Carbon | 2 | 1989 | 687 | 0.030 |
Why?
|
| Neuropsychological Tests | 2 | 2006 | 6993 | 0.030 |
Why?
|
| Exostoses | 1 | 1975 | 30 | 0.030 |
Why?
|
| Zimbabwe | 1 | 2015 | 129 | 0.030 |
Why?
|
| Equipment Failure | 1 | 2018 | 578 | 0.030 |
Why?
|
| Methotrexate | 1 | 2002 | 1727 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 6895 | 0.030 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2006 | 113 | 0.030 |
Why?
|
| Age Factors | 2 | 2018 | 18370 | 0.030 |
Why?
|
| Heterozygote | 1 | 2001 | 2804 | 0.030 |
Why?
|
| Prevalence | 2 | 2008 | 15226 | 0.030 |
Why?
|
| Massachusetts | 2 | 2016 | 8663 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2006 | 2026 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2016 | 430 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1999 | 685 | 0.030 |
Why?
|
| Benchmarking | 1 | 2020 | 1042 | 0.030 |
Why?
|
| Spondylitis, Ankylosing | 1 | 1975 | 156 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2000 | 3588 | 0.030 |
Why?
|
| Phenotype | 2 | 2001 | 16365 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2005 | 2838 | 0.030 |
Why?
|
| Developing Countries | 1 | 2006 | 2815 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2006 | 3297 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2000 | 972 | 0.030 |
Why?
|
| Mammography | 1 | 2004 | 2476 | 0.030 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1997 | 547 | 0.030 |
Why?
|
| Antirheumatic Agents | 1 | 2002 | 1339 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 1993 | 666 | 0.030 |
Why?
|
| Birth Weight | 2 | 1999 | 2069 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2012 | 6600 | 0.030 |
Why?
|
| El Salvador | 1 | 1991 | 39 | 0.030 |
Why?
|
| Endometrial Neoplasms | 1 | 2001 | 1353 | 0.020 |
Why?
|
| Lung Neoplasms | 3 | 1998 | 13102 | 0.020 |
Why?
|
| Tanzania | 2 | 2006 | 1346 | 0.020 |
Why?
|
| Toxoplasmosis | 1 | 1991 | 91 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1999 | 2765 | 0.020 |
Why?
|
| Uganda | 1 | 2015 | 1243 | 0.020 |
Why?
|
| Wisconsin | 1 | 2010 | 124 | 0.020 |
Why?
|
| Young Adult | 4 | 2021 | 56430 | 0.020 |
Why?
|
| Bipolar Disorder | 1 | 2007 | 5027 | 0.020 |
Why?
|
| Registries | 1 | 2005 | 8089 | 0.020 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2010 | 162 | 0.020 |
Why?
|
| Alleles | 1 | 2000 | 6933 | 0.020 |
Why?
|
| Sulfur Dioxide | 1 | 1989 | 177 | 0.020 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1988 | 40 | 0.020 |
Why?
|
| Asbestos | 1 | 1991 | 251 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1999 | 4328 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 1997 | 1061 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1993 | 2274 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 1993 | 1344 | 0.020 |
Why?
|
| Rwanda | 1 | 2011 | 703 | 0.020 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 3966 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1989 | 623 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 57776 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2010 | 319 | 0.020 |
Why?
|
| Accidents, Home | 1 | 1988 | 75 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2000 | 3748 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1504 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 1992 | 789 | 0.020 |
Why?
|
| Silicosis | 1 | 1986 | 45 | 0.020 |
Why?
|
| Containment of Biohazards | 1 | 2006 | 37 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2002 | 3712 | 0.020 |
Why?
|
| Eating | 1 | 2013 | 1536 | 0.020 |
Why?
|
| Psychotic Disorders | 1 | 2001 | 3046 | 0.020 |
Why?
|
| Antipsychotic Agents | 2 | 2015 | 3057 | 0.020 |
Why?
|
| Depression | 1 | 2005 | 7766 | 0.020 |
Why?
|
| Animals | 5 | 2013 | 168757 | 0.020 |
Why?
|
| Ethics, Medical | 1 | 1991 | 792 | 0.020 |
Why?
|
| Health Promotion | 1 | 2017 | 2205 | 0.020 |
Why?
|
| Maximal Expiratory Flow Rate | 1 | 1984 | 44 | 0.020 |
Why?
|
| Family Health | 1 | 2010 | 1282 | 0.020 |
Why?
|
| Respiratory Function Tests | 2 | 1986 | 1616 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2020 | 4599 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 1991 | 819 | 0.020 |
Why?
|
| Forced Expiratory Flow Rates | 1 | 1984 | 74 | 0.020 |
Why?
|
| Overweight | 1 | 2016 | 2371 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1996 | 2408 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 10943 | 0.010 |
Why?
|
| Maximum Allowable Concentration | 1 | 1983 | 62 | 0.010 |
Why?
|
| Genotype | 1 | 1998 | 12951 | 0.010 |
Why?
|
| Hong Kong | 1 | 2003 | 148 | 0.010 |
Why?
|
| Patient Isolation | 1 | 2003 | 100 | 0.010 |
Why?
|
| Multivariate Analysis | 2 | 1996 | 12245 | 0.010 |
Why?
|
| Morbidity | 1 | 1988 | 1769 | 0.010 |
Why?
|
| Singapore | 1 | 2003 | 295 | 0.010 |
Why?
|
| Cities | 1 | 2004 | 513 | 0.010 |
Why?
|
| Communicable Disease Control | 2 | 2004 | 857 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2015 | 8324 | 0.010 |
Why?
|
| Spirometry | 1 | 1984 | 864 | 0.010 |
Why?
|
| Lead Poisoning | 1 | 1983 | 301 | 0.010 |
Why?
|
| Quarantine | 1 | 2003 | 170 | 0.010 |
Why?
|
| Longevity | 1 | 1988 | 1070 | 0.010 |
Why?
|
| Contact Tracing | 1 | 2003 | 273 | 0.010 |
Why?
|
| Disaster Planning | 1 | 2006 | 549 | 0.010 |
Why?
|
| Malaria | 1 | 1990 | 1239 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6538 | 0.010 |
Why?
|
| Lung | 2 | 1989 | 9856 | 0.010 |
Why?
|
| Tuberculosis | 1 | 2011 | 1912 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1985 | 1257 | 0.010 |
Why?
|
| Lead | 1 | 1983 | 852 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 1901 | 0.010 |
Why?
|
| Health Behavior | 1 | 2009 | 2636 | 0.010 |
Why?
|
| Physicians | 1 | 2015 | 4567 | 0.010 |
Why?
|
| Placebos | 1 | 2001 | 1676 | 0.010 |
Why?
|
| Burns | 1 | 1988 | 1815 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 5751 | 0.010 |
Why?
|
| Heel | 1 | 1975 | 36 | 0.010 |
Why?
|
| Elbow | 1 | 1975 | 138 | 0.010 |
Why?
|
| Health Policy | 1 | 2006 | 2661 | 0.010 |
Why?
|
| Knee | 1 | 1975 | 274 | 0.010 |
Why?
|
| Wrist | 1 | 1975 | 224 | 0.010 |
Why?
|
| Humerus | 1 | 1975 | 266 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 2749 | 0.010 |
Why?
|
| Pelvic Bones | 1 | 1975 | 265 | 0.010 |
Why?
|
| Forearm | 1 | 1975 | 409 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 1996 | 850 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 11725 | 0.010 |
Why?
|
| Occupations | 2 | 1984 | 517 | 0.010 |
Why?
|
| Foot | 1 | 1975 | 527 | 0.010 |
Why?
|
| Leukemia | 1 | 1999 | 1511 | 0.010 |
Why?
|
| Thoracic Vertebrae | 1 | 1975 | 608 | 0.010 |
Why?
|
| Leg | 1 | 1975 | 1116 | 0.010 |
Why?
|
| Age of Onset | 1 | 1996 | 3271 | 0.010 |
Why?
|
| Hand | 1 | 1975 | 884 | 0.010 |
Why?
|
| Aging | 2 | 1986 | 8664 | 0.010 |
Why?
|
| Syndrome | 1 | 1975 | 3251 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 1990 | 221 | 0.010 |
Why?
|
| Femur | 1 | 1975 | 1297 | 0.010 |
Why?
|
| Cervical Vertebrae | 1 | 1975 | 975 | 0.010 |
Why?
|
| Immunization, Secondary | 1 | 1990 | 340 | 0.000 |
Why?
|
| Vital Capacity | 1 | 1989 | 925 | 0.000 |
Why?
|
| Dust | 1 | 1989 | 482 | 0.000 |
Why?
|
| National Health Programs | 1 | 1990 | 445 | 0.000 |
Why?
|
| Lumbar Vertebrae | 1 | 1975 | 1848 | 0.000 |
Why?
|
| Brazil | 1 | 1990 | 1270 | 0.000 |
Why?
|
| Radiography | 1 | 1975 | 7023 | 0.000 |
Why?
|
| Immunity | 1 | 1990 | 1012 | 0.000 |
Why?
|
| Edetic Acid | 1 | 1983 | 276 | 0.000 |
Why?
|
| Connecticut | 1 | 1983 | 366 | 0.000 |
Why?
|
| Employment | 1 | 1989 | 1132 | 0.000 |
Why?
|
| Blood Cell Count | 1 | 1983 | 403 | 0.000 |
Why?
|
| Hematocrit | 1 | 1983 | 636 | 0.000 |
Why?
|
| Hemolysis | 1 | 1983 | 420 | 0.000 |
Why?
|
| Program Evaluation | 1 | 1990 | 2488 | 0.000 |
Why?
|
| Anemia | 1 | 1983 | 1506 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1983 | 9146 | 0.000 |
Why?
|
| Cross-Sectional Studies | 1 | 1986 | 25043 | 0.000 |
Why?
|
| Neoplasms | 1 | 1985 | 21683 | 0.000 |
Why?
|